Forsyth scientists gain new understanding of latent tuberculosis

TB hides in bone marrow stem cells

2013-01-31

(Press-News.org) Scientists at the Forsyth have gained new insight on how Tuberculosis (TB) remains a global epidemic. Although drugs have been available to fight TB for 50 years, the disease still infects nearly 2.2 billion people worldwide and causes 1.7 million annual deaths. This is largely attributed to the bacteria's ability to stay dormant in the human body and later resurface as active disease. The Forsyth team, and its collaborators from Stanford University, has recently discovered that Mycobacterium tuberculosis, the bacteria that causes TB, can lay dormant and thrive within bone marrow stem cells.

The microbe Mycobacterium tuberculosis (Mtb) causes deadly disease in millions of humans and infects and persists in billions of others without causing apparent harm, yet maintaining the potential to "re-activate" and cause active tuberculosis (TB). This form of silent microbe/host interaction is known as latent or dormant TB infection. During this phase, Mtb escapes the host immune responses and survives for decades in protected niches not yet well identified. This study describes a previously unsuspected target cell used by Mtb to shield itself from the host immune system. These new findings have direct clinical implications in that they explain the reason why TB treated patients remain sensitive to TB tests for life and importantly, why TB treatment is so difficult and requires long periods of drug treatment. Moreover, these findings raise an alert for possible transmission of TB to patients undergoing bone marrow transplants with cells obtained from donors who may have latent TB.

This study, which will be published in Science Translational Medicine on January 30, 2013, was led at Forsyth by Dr. Antonio Campos-Neto, Director of Forsyth's Center for Global Infectious Diseases. The work was done in collaboration with Drs. Bikul Das and Dean Flesher from Stanford University, School of Medicine; Dr. Suely S. Kashino from Forsyth Institute, Drs. Ista Pulu and Vijay Swami, Research Institute of World's Ancient Traditions, Cultures and Heritages; Dr. Deepjyoti Kalita, KaviKrishna Foundation and Guwahati Medical College; and Dr. Hermen Yeger, the Hospital for Sick Children in Toronto."Tuberculosis has remained a terrible health threat despite the proliferation of knowledge, diagnostics and treatment," said Dr. Campos-Neto. "By gaining a greater understanding of latent TB, we can potentially save hundreds of thousands of lives each year."

Summary of Study Dr. Campos-Neto and his team conducted in vitro experiments, as well as in vivo using a well-defined animal model of latent TB, and from data collected from human patients treated for TB. From these studies they concluded that Mtb infects and persists in a dormant state for long periods of time within bone marrow (BM) stem cells. These cells constitute a unique niche or a sanctuary that provides the pathogen both immune privilege and protection from drug attack. Stem cells, like those infected by Mtb, are long living cells and possess a special machinery to exclude external molecules such as anti-TB drugs to enter their cytoplasm. Therefore, once inside these cells, Mtb benefits from this mechanism for its survival in a quiescent manner.

### This study was funding in part by grants from National Institute of Allergy and Infectious Diseases (NIAID) www.niaid.nih.gov/.

About Forsyth The Forsyth Institute is the world's leading independent organization dedicated to scientific research and education in oral health and related biomedical sciences. Established in 1910, Forsyth's goal is to lead the discovery, communication and application of breakthroughs in oral health and disease prevention that will significantly improve the health and well-being of the nation and the world. For more information about Forsyth, visit its website at www.forsyth.org.

ELSE PRESS RELEASES FROM THIS DATE:

Itching for new help for eczema: Recently identified immune cells possible therapeutic target

2013-01-31

PHILADELPHIA - The increasing incidence of allergic skin diseases, and the accompanying economic burden and heightened risk of developing other allergic conditions, have spurred researchers to look for better ways to control these immune system-based disorders. Atopic dermatitis, more commonly called eczema, now affects 10 to 20 percent of children in the United States and direct health-care costs exceed $3 billion, according to the National Institute of Arthritis and Musculoskeletal and Skin Diseases. What's more, up to 50 percent of children with atopic dermatitis ...

Scientists may have received millions in duplicate funding

2013-01-31

Big Data computation at the Virginia Bioinformatics Institute at Virginia Tech reveals that over the past two decades funding agencies may have awarded millions and possibly billions of dollars to scientists who submitted the same grant request multiple times — and accepted duplicate funding. An analysis led by Harold R. Garner, a professor at Virginia Tech, not only indicates that millions in funding may have been granted and used inappropriately, it points to techniques to uncover existing instances of duplicate funding and ways to prevent it in the future. The analysis ...

Setting the stage for a new paradigm in treatment of heart failure

2013-01-31

CHAPEL HILL, N.C. – Despite a substantial increase in the number of people suffering the debilitating and often deadly effects of heart failure, treatments for the condition have not advanced significantly for at least 10 years. An analysis by researchers at the University of North Carolina School of Medicine shows new breakthroughs could be closer than we thought. The analysis points to striking similarities between heart cells in patients with heart failure and brain cells in patients with Alzheimer's disease, raising the possibility that some treatment approaches being ...

Current evidence does not support selenium for preventing heart disease in well-nourished adults

2013-01-31

A systematic review published today in The Cochrane Library finds that in well-nourished adults current evidence does not support selenium for preventing heart disease. The review suggests that taking selenium supplements does not reduce a person's risk of developing heart disease, although most evidence is currently limited to healthy American adults. Diet is a key factor influencing heart disease risk. Selenium is one dietary element that could potentially play a role in preventing heart disease by protecting against oxidative stress and inflammation. It is a common ...

Brain activity study lends insight into schizophrenia

2013-01-31

Magnetic fields produced by the naturally occurring electrical currents in the brain could potentially be used as an objective test for schizophrenia and help to better understand the disease, according to new research published today. A team of researchers from Plymouth and Spain have used the non-invasive magnetoencephalogram (MEG) technique to find two spectral features that are significantly different in schizophrenia patients compared to healthy control subjects. Furthermore, they found that there were four spectral features in the brain signals of schizophrenia ...

Dementia: Cerebrolysin shows promise

2013-01-31

Dementia patients may benefit from a promising new treatment called Cerebrolysin, according to the results of a systematic review published in The Cochrane Library. The authors brought together the most up-to-date evidence on Cerebrolysin as a treatment for vascular dementia. Vascular dementia is a common form of dementia caused by damage to the network of blood vessels supplying the brain. Some of the symptoms are similar to those associated with Alzheimer's disease and stroke but in particular those with vascular dementia often experience difficulty thinking quickly, ...

Chronic hepatitis C: Interferon may be harmful in re-treatment

2013-01-31

People with hepatitis C and chronic liver disease who relapsed or failed to respond to initial treatment are unlikely to improve on interferon retreatment. In fact, they may face an increased risk of dying sooner, and are likely to experience a variety of adverse effects, according to an updated systematic review published in The Cochrane Library. Hepatitis C affects around 170 million people worldwide. In some cases, infection leads to chronic liver disease, liver failure or liver cancer, eventually resulting in death. Treatment is based on antiviral drugs. Interferon ...

Tuberculosis: WHO-endorsed test offers rapid detection

2013-01-31

A diagnostic test for tuberculosis (TB) can accurately and quickly detect both TB and drug-resistant strains, according to a new study. The authors of a new systematic review assessing the diagnostic accuracy of the Xpert® MTB/RIF test published in The Cochrane Library say their study can provide timely advice for clinicians and policymakers in countries where TB is a major public health problem. Millions of people develop TB every year. Around 13% of cases occur in people living with HIV and more than a quarter of these people die as a result. Drug resistance is a major ...

New research shows complexity of global warming

2013-01-31

Global warming from greenhouse gases affects rainfall patterns in the world differently than that from solar heating, according to a study by an international team of scientists in the January 31 issue of Nature. Using computer model simulations, the scientists, led by Jian Liu (Chinese Academy of Sciences) and Bin Wang (International Pacific Research Center, University of Hawaii at Manoa), showed that global rainfall has increased less over the present-day warming period than during the Medieval Warm Period, even though temperatures are higher today than they were then. ...

Tuberculosis may lurk in bone marrow stem cells of infected patients, Stanford researchers say

2013-01-31

STANFORD, Calif. - Tuberculosis is a devastating disease that kills nearly 2 million people worldwide each year. Although antibiotics exist that can ameliorate the symptoms, the courses of therapy last for months and don't completely eradicate the disease, which frequently recurs years or decades after the initial treatment. Now, in a classic case of bench-to-bedside research, scientists at the Stanford University School of Medicine have discovered a possible reason for the disease's resistance: The ability of the tuberculosis bacteria to infiltrate and settle down in ...

LAST 30 PRESS RELEASES:

AI finds undiagnosed liver disease in early stages

The American Society of Tropical Medicine and Hygiene and the Bill & Melinda Gates Foundation announce new research fellowship in malaria genomics in honor of professor Dominic Kwiatkowski